AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
inositol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1444 | 87-89-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK | 33 | |||
| kinase-selectivity-class | ACVRL1,AURKB,AXL,BMX,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK8,CDK9,CHUK,DYRK1A,EPHB4,IGF1R,INSR,IRAK1,IRAK3,IRAK4,MAP2K6,MAP3K14,MAP3K21,PDK1,PIK3CB,PIK3CD,PRKDC,TEK,TGFBR1,ZAP70 | 31 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lip dry | 74.84 | 32.79 | 53 | 4679 | 100902 | 90522813 |
| Back disorder | 67.85 | 32.79 | 31 | 4701 | 25600 | 90598115 |
| C-reactive protein abnormal | 65.96 | 32.79 | 54 | 4678 | 127375 | 90496340 |
| Incorrect route of product administration | 55.59 | 32.79 | 34 | 4698 | 50592 | 90573123 |
| Dislocation of vertebra | 54.94 | 32.79 | 35 | 4697 | 55933 | 90567782 |
| Adjustment disorder with depressed mood | 54.49 | 32.79 | 35 | 4697 | 56718 | 90566997 |
| Injury | 51.03 | 32.79 | 57 | 4675 | 197292 | 90426423 |
| Breast cancer stage II | 50.07 | 32.79 | 28 | 4704 | 35306 | 90588409 |
| Rheumatoid factor positive | 48.59 | 32.79 | 52 | 4680 | 171598 | 90452117 |
| Oedema | 43.67 | 32.79 | 53 | 4679 | 200242 | 90423473 |
| Musculoskeletal pain | 40.09 | 32.79 | 47 | 4685 | 171204 | 90452511 |
| Prescribed underdose | 37.12 | 32.79 | 31 | 4701 | 74988 | 90548727 |
| Amnesia | 36.33 | 32.79 | 36 | 4696 | 108469 | 90515246 |
| Delirium | 35.64 | 32.79 | 35 | 4697 | 104324 | 90519391 |
| Anti-cyclic citrullinated peptide antibody positive | 35.29 | 32.79 | 52 | 4680 | 236381 | 90387334 |
| Joint range of motion decreased | 34.72 | 32.79 | 39 | 4693 | 135604 | 90488111 |
| Peripheral venous disease | 34.11 | 32.79 | 31 | 4701 | 83890 | 90539825 |
| Prescribed overdose | 33.82 | 32.79 | 33 | 4699 | 97592 | 90526123 |
| Fluid retention | 32.82 | 32.79 | 31 | 4701 | 88060 | 90535655 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lip dry | 85.84 | 46.63 | 56 | 5329 | 100027 | 110483887 |
| Back disorder | 79.42 | 46.63 | 32 | 5353 | 20890 | 110563024 |
| Needle fatigue | 78.65 | 46.63 | 17 | 5368 | 1247 | 110582667 |
| Gait spastic | 75.21 | 46.63 | 17 | 5368 | 1532 | 110582382 |
| C-reactive protein abnormal | 72.76 | 46.63 | 56 | 5329 | 129639 | 110454275 |
| Relapsing-remitting multiple sclerosis | 70.20 | 46.63 | 17 | 5368 | 2065 | 110581849 |
| Dislocation of vertebra | 68.04 | 46.63 | 36 | 5349 | 43685 | 110540229 |
| Adjustment disorder with depressed mood | 67.92 | 46.63 | 36 | 5349 | 43847 | 110540067 |
| Rheumatoid factor positive | 67.70 | 46.63 | 54 | 5331 | 131586 | 110452328 |
| Injury | 65.21 | 46.63 | 60 | 5325 | 177205 | 110406709 |
| Breast cancer stage II | 58.65 | 46.63 | 28 | 5357 | 27347 | 110556567 |
| Monoparesis | 57.02 | 46.63 | 17 | 5368 | 4536 | 110579378 |
| Hypertonic bladder | 54.47 | 46.63 | 17 | 5368 | 5285 | 110578629 |
| Anti-cyclic citrullinated peptide antibody positive | 52.64 | 46.63 | 54 | 5331 | 181930 | 110401984 |
| Incorrect route of product administration | 50.43 | 46.63 | 34 | 5351 | 64027 | 110519887 |
| Oedema | 49.65 | 46.63 | 56 | 5329 | 209920 | 110373994 |
| Discomfort | 48.63 | 46.63 | 56 | 5329 | 214651 | 110369263 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A11HA07 | ALIMENTARY TRACT AND METABOLISM VITAMINS OTHER PLAIN VITAMIN PREPARATIONS Other plain vitamin preparations |
| MeSH PA | D014803 | Vitamin B Complex |
| MeSH PA | D014815 | Vitamins |
| MeSH PA | D018977 | Micronutrients |
| CHEBI has role | CHEBI:23366 | compatible osmolytes |
| CHEBI has role | CHEBI:33284 | nutrient |
| CHEBI has role | CHEBI:64763 | EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75772 | <em>Saccharomyces cerevisiae </em> metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:83056 | <em>Daphnia magna</em> metabolite |
Related Drugs by ATC class:
A11HA Other plain vitamin preparations 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypercholesterolemia | indication | 13644009 | |
| Hypoalphalipoproteinemia | indication | 190785000 | |
| Mixed hyperlipidemia | indication | 267434003 | |
| Hypertriglyceridemia | indication | 302870006 | |
| Pellagra | indication | 418186002 | DOID:8457 |
| Niacin deficiency | indication | 418279001 | |
| Slow Progression of Coronary Artery Disease | indication | ||
| Myocardial Reinfarction Prevention | indication | ||
| Hyperlipidemia | off-label use | 55822004 | DOID:1168 |
| Hypophosphatemia | contraindication | 4996001 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Acute cerebrovascular insufficiency | contraindication | 29322000 | |
| Low blood pressure | contraindication | 45007003 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Gout | contraindication | 90560007 | DOID:13189 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Arterial hemorrhage | contraindication | 234003006 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Acute coronary syndrome | contraindication | 394659003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Cerebral infarction | contraindication | 432504007 | DOID:3526 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.21 | acidic |
| pKa2 | 13.31 | acidic |
| pKa3 | 13.71 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4017688 | VUID |
| N0000146062 | NUI |
| D08079 | KEGG_DRUG |
| 4017688 | VANDF |
| C0021547 | UMLSCUI |
| CHEBI:17268 | CHEBI |
| INS | PDB_CHEM_ID |
| CHEMBL1222251 | ChEMBL_ID |
| DB13178 | DRUGBANK_ID |
| D007294 | MESH_DESCRIPTOR_UI |
| 892 | PUBCHEM_CID |
| 10437 | INN_ID |
| 4L6452S749 | UNII |
| 5833 | RXNORM |
| 4879 | MMSL |
| 5751 | MMSL |
| d00496 | MMSL |
| 002057 | NDDF |
| 108960004 | SNOMEDCT_US |
| 72164009 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Lipovite | HUMAN PRESCRIPTION DRUG LABEL | 13 | 70104-128 | INJECTION | 1 mg | INTRAMUSCULAR | unapproved drug other | 1 sections |
| MIC B12 | HUMAN PRESCRIPTION DRUG LABEL | 4 | 70104-806 | INJECTION | 1 mg | INTRAMUSCULAR | unapproved drug other | 1 sections |
| NEONATAL PLUS VITAMIN | HUMAN PRESCRIPTION DRUG LABEL | 17 | 70898-115 | TABLET | 5 mg | ORAL | unapproved drug other | 9 sections |
| One Natal Rx | HUMAN PRESCRIPTION DRUG LABEL | 17 | 82568-0141 | TABLET | 5 mg | ORAL | unapproved drug other | 4 sections |
| Deep Repair DARK SPOT | HUMAN OTC DRUG LABEL | 5 | 84867-001 | CREAM | 1000 mg | CUTANEOUS | OTC Monograph Drug | 10 sections |
| HANYWIL Deep Repair DARK SPOT | HUMAN OTC DRUG LABEL | 5 | 84867-002 | CREAM | 1000 mg | CUTANEOUS | OTC Monograph Drug | 11 sections |
| HANYWIL-DARK SPOT | HUMAN OTC DRUG LABEL | 5 | 84867-003 | CREAM | 1000 mg | CUTANEOUS | OTC Monograph Drug | 11 sections |
| HANYWIL DARK SPOT | HUMAN OTC DRUG LABEL | 5 | 84867-004 | SOLUTION, GEL FORMING / DROPS | 1500 mg | CUTANEOUS | OTC Monograph Drug | 11 sections |